Formosa Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019
March 29, 2020 at 05:00 pm
Share
Formosa Laboratories, Inc. announced earnings results for the full year ended December 31, 2019. For the full year, the company announced sales was TWD 2,759.591 million compared to TWD 2,687.731 million a year ago. Operating income was TWD 24.438 million compared to TWD 60.484 million a year ago. Net income was TWD 11.631 million compared to TWD 176.821 million a year ago. Basic earnings per share was TWD 0.12 compared to TWD 1.85 a year ago. Diluted earnings per share was TWD 0.12 compared to TWD 1.78 a year ago.
Formosa Laboratories, Inc. is a Taiwan-based company principally engaged in the development, production and distribution of ultraviolet (UV)-proof active ingredients, bulk pharmaceutical chemicals, antibody drug conjugates, as well as the provision of customized services. The Company primarily provides UV-proof active ingredients series products, vitamin D derivative series products, anti-inflammatory analgesic series products, steroid, anti-cancer drugs, cholesterol phosphate binding agents, nuclear magnetic resonance (NMR) reagents, respiratory disease drugs, central nervous system drugs, immune system regulators and weight loss drugs, as well as customized research and development and original equipment manufacturing (OEM) services. The Company distributes its products to Europe, the Americas, Asia and other markets.
FORMOSA LABORATORIES, INC. 
